Our Clinical Candidate

Mocravimod is a modulator of sphingosine-1-phosphate (S1P) receptors. Priothera is developing mocravimod in AML with the aim of enhancing the curative potential of Hematopoietic Stem Cell Transplantation (HSCT). Promising early clinical results have revealed that mocravimod has the potential to decouple Graft-versus-Host Disease (GvHD)  from Graft-versus-Leukemia  (GvL),  by preventing the first and preserving the latter.